D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02744768

Recruitment Status : Unknown

Verified March 2018 by Gruppo Italiano Malattie EMatologiche dell'Adulto.
Recruitment status was: Recruiting

First Posted : April 20, 2016

Last Update Posted : March 22, 2018

View this study on the modernized ClinicalTrials.gov

Sponsor:

Information provided by (Responsible Party):

Gruppo Italiano Malattie EMatologiche dell'Adulto

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Unknown
Estimated Primary Completion Date :	June 2021
Estimated Study Completion Date :	June 2021

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Foa R, Bassan R, Vitale A, Elia L, Piciocchi A, Puzzolo MC, Canichella M, Viero P, Ferrara F, Lunghi M, Fabbiano F, Bonifacio M, Fracchiolla N, Di Bartolomeo P, Mancino A, De Propris MS, Vignetti M, Guarini A, Rambaldi A, Chiaretti S; GIMEMA Investigators. Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults. N Engl J Med. 2020 Oct 22;383(17):1613-1623. doi: 10.1056/NEJMoa2016272.

To Top